|
ATE180280T1
(de)
|
1991-03-05 |
1999-06-15 |
Wellcome Found |
Expression rekombinanter proteine in attenuierten bakterien
|
|
US5981724A
(en)
|
1991-10-25 |
1999-11-09 |
Immunex Corporation |
DNA encoding CD40 ligand, a cytokine that binds CD40
|
|
US7405270B2
(en)
|
1991-10-25 |
2008-07-29 |
Immunex Corporation |
CD40-Ligand lacking native-pattern glycosylation
|
|
US5962406A
(en)
|
1991-10-25 |
1999-10-05 |
Immunex Corporation |
Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
|
|
KR100283541B1
(ko)
|
1991-10-25 |
2001-03-02 |
크리스토퍼 엘. 와이트, 스코트 지. 홀퀴스트, 스티븐 엘. 말라스카 |
신규 사이토킨
|
|
CA2143299A1
(en)
|
1992-09-04 |
1994-03-17 |
University Of Saskatchewan |
Novel bacterial vaccines using vaccine strains of pathogenic bacteria
|
|
WO1995014487A1
(en)
|
1993-11-24 |
1995-06-01 |
The Australian National University |
Treatment of viral disease with cd40l peptide
|
|
AU699291B2
(en)
|
1995-03-01 |
1998-11-26 |
Immunex Corporation |
Method for stimulating an immune response
|
|
MX9709447A
(es)
|
1995-06-07 |
1998-02-28 |
Immunex Corp |
Nueva muteina cd4ol.
|
|
US6479258B1
(en)
|
1995-12-07 |
2002-11-12 |
Diversa Corporation |
Non-stochastic generation of genetic vaccines
|
|
US6713279B1
(en)
|
1995-12-07 |
2004-03-30 |
Diversa Corporation |
Non-stochastic generation of genetic vaccines and enzymes
|
|
US6306387B1
(en)
|
1997-05-29 |
2001-10-23 |
The Research Foundation Of State University Of New York |
Antigen delivery system
|
|
US20030045492A1
(en)
|
1997-08-13 |
2003-03-06 |
Tang De-Chu C. |
Vaccination by topical application of recombinant vectors
|
|
US6969609B1
(en)
|
1998-12-09 |
2005-11-29 |
The United States Of America As Represented By The Department Of Health And Human Serivces |
Recombinant vector expressing multiple costimulatory molecules and uses thereof
|
|
CA2223225A1
(en)
|
1997-11-28 |
1999-05-28 |
Canadian Red Cross Society |
Method for inhibiting in vivo immune response
|
|
JP2001526241A
(ja)
|
1997-12-19 |
2001-12-18 |
イミュネックス・コーポレーション |
Ｈｉｖ感染に対する感受性を低下させるための方法
|
|
GB9806449D0
(en)
|
1998-03-25 |
1998-05-27 |
Peptide Therapeutics Ltd |
Attenuated bacteria useful in vaccines
|
|
US6190669B1
(en)
|
1998-05-13 |
2001-02-20 |
University Of Maryland, Baltimore |
Attenuated mutants of salmonella which constitutively express the Vi antigen
|
|
IT1299583B1
(it)
|
1998-05-19 |
2000-03-16 |
Vander Way Limited |
Uso di proteine hmg-i per la preparazione di medicamenti ad attivita' citotossica
|
|
WO2000014240A2
(en)
|
1998-09-04 |
2000-03-16 |
Creatogen Aktiengesellschaft |
Attenuated salmonella sp12 mutants as antigen carriers
|
|
US7300774B1
(en)
|
1999-12-09 |
2007-11-27 |
The Regents Of The University Of California |
Multimeric fusion proteins of the TNF superfamily ligands
|
|
JP2003508016A
(ja)
|
1999-04-16 |
2003-03-04 |
エフ．ホフマン−ラ ロシュ アーゲー |
Ｃｄ４０／ｃｄ４０ｌキメラポリペプチドをコードする核酸、それらの生成方法及びそれらの使用
|
|
EP1067194A1
(en)
|
1999-04-16 |
2001-01-10 |
F. Hoffmann-La Roche Ag |
Vectors containing a gene coding for CD40 and/or CD40L under the control of a cytokine-inducible promoter which is a human acute phase amyloid A gene promoter. Methods for their production and uses thereof
|
|
EP1246643A4
(en)
|
1999-10-14 |
2005-05-11 |
Jeffery A Ledbetter |
DNA VACCINES ENCODING ANTIGEN ASSOCIATED WITH CD40-BINDING DOMAIN
|
|
MXPA00012796A
(es)
|
1999-12-28 |
2002-05-23 |
Akzo Nobel Nv |
Vacuna de salmonella.
|
|
DE60136334D1
(en)
|
2000-02-02 |
2008-12-11 |
Us Health |
Cd40-ligand als adjuvant für respiratorisches syncytialvirus-impfstoff
|
|
AU5695701A
(en)
|
2000-03-17 |
2001-10-03 |
Upjohn Co |
Salmonella vaccine materials and methods
|
|
GB0015426D0
(en)
|
2000-06-24 |
2000-08-16 |
Univ Southampton |
Method for generating soluble highly multimeric proteins
|
|
AU2001273009A1
(en)
|
2000-06-26 |
2002-01-08 |
Maxygen, Inc. |
Methods and compositions for developing spore display systems for medicinal and industrial applications
|
|
AU2002221780A1
(en)
|
2000-10-31 |
2002-05-15 |
F.Hoffmann-La Roche Ag |
Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
|
|
EP1407004B1
(en)
|
2001-05-15 |
2009-08-05 |
Ortho-McNeil-Janssen Pharmaceuticals, Inc. |
Ex-vivo priming for generating cd40-ligand specific cytotoxic t lymphocytes to treat autoimmune and allergic disease
|
|
BR0209689A
(pt)
|
2001-05-15 |
2006-02-07 |
Long Island Jewish Res Inst |
Uso de fragmento de hmg como agente anti-inflamatório
|
|
US7220723B2
(en)
|
2001-05-15 |
2007-05-22 |
The Feinstein Institute For Medical Research |
Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
|
|
ITMI20011986A1
(it)
|
2001-09-25 |
2003-03-25 |
San Raffaele Centro Fond |
Metodo e composizione per l'attivazione di cellule presentanti l'antigene
|
|
CA2470640A1
(en)
|
2001-12-19 |
2003-06-26 |
Alcedo Biotech Gmbh |
Use of hmgb proteins and nucleic acids that code therefor
|
|
US6923958B2
(en)
|
2002-03-02 |
2005-08-02 |
The Scripps Research Institute |
DNA vaccines encoding CEA and a CD40 ligand and methods of use thereof
|
|
WO2003096812A1
(en)
|
2002-04-15 |
2003-11-27 |
Washington University |
Regulated attenuation of live vaccines to enhance cross protective immunogenicity
|
|
US7495090B2
(en)
|
2002-05-23 |
2009-02-24 |
The Regents Of The University Of California |
Nucleic acids encoding chimeric CD154 polypeptides
|
|
WO2004046345A2
(en)
|
2002-11-20 |
2004-06-03 |
Critical Therapeutics, Inc. |
Use of hmgb fragments as anti-inflammatory agents
|
|
US20040156851A1
(en)
|
2002-11-20 |
2004-08-12 |
Critical Therapeutics, Inc. |
HMGB1 combination therapies
|
|
US20040141948A1
(en)
|
2002-11-20 |
2004-07-22 |
Critical Therapeutics, Inc. |
Use of HMGB fragments as anti-inflammatory agents
|
|
AU2003295653B2
(en)
|
2002-11-20 |
2007-08-16 |
The Feinstein Institute Of Medical Research |
Use of HMGB polypeptides for increasing immune responses
|
|
US20050181994A1
(en)
|
2003-01-06 |
2005-08-18 |
Xencor, Inc. |
Novel variants of CD40L protein
|
|
US20060014248A1
(en)
|
2003-01-06 |
2006-01-19 |
Xencor, Inc. |
TNF super family members with altered immunogenicity
|
|
US7696169B2
(en)
|
2003-06-06 |
2010-04-13 |
The Feinstein Institute For Medical Research |
Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
|
|
US7754209B2
(en)
|
2003-07-26 |
2010-07-13 |
Trubion Pharmaceuticals |
Binding constructs and methods for use thereof
|
|
WO2005025604A2
(en)
|
2003-09-10 |
2005-03-24 |
The General Hospital Corporation |
Use of hmgb and hmgb fragments to decrease specific immune response
|
|
WO2005035570A2
(en)
|
2003-10-10 |
2005-04-21 |
Xencor, Inc. |
Variants of cd40l protein
|
|
US8828957B2
(en)
|
2003-12-11 |
2014-09-09 |
Microvax, Llc |
Methods for generating immunity to antigen
|
|
WO2005058950A2
(en)
|
2003-12-11 |
2005-06-30 |
Sidney Kimmel Cancer Center |
Methods for generating immunity to antigen
|
|
WO2005103073A2
(en)
|
2004-04-27 |
2005-11-03 |
Intercell Ag |
Td antigens
|
|
WO2005113598A2
(en)
|
2004-05-21 |
2005-12-01 |
Xencor, Inc. |
Tnf super family members with altered immunogenicity
|
|
WO2006083301A2
(en)
*
|
2004-06-17 |
2006-08-10 |
Medimmune, Inc. |
Immunogenic compositions comprising hmgb1 polypeptides
|
|
EP1814576A2
(en)
|
2004-07-20 |
2007-08-08 |
Critical Therapeutics, Inc. |
Combination therapies of hmgb and complement inhibitors against inflammation
|
|
US8513008B2
(en)
|
2004-10-07 |
2013-08-20 |
Argos Therapeutics, Inc. |
Mature dendritic cell compositions and methods for culturing same
|
|
US20080145931A1
(en)
|
2004-10-07 |
2008-06-19 |
Argos Therapeutics, Inc. |
Mature Dendritic Cell Compositions and Methods of Culturing Same
|
|
GB0423681D0
(en)
|
2004-10-26 |
2004-11-24 |
Sec Dep For Environment Food & |
Vaccine and nucleic acids
|
|
WO2006069262A2
(en)
|
2004-12-21 |
2006-06-29 |
Vaxinnate Corporation |
Compositions of influenza viral proteins and methods of use thereof
|
|
WO2006105972A1
(en)
|
2005-04-07 |
2006-10-12 |
Universite Libre De Bruxelles |
Transgenic organism expressing cd40l and uses thereof
|
|
WO2006130525A2
(en)
|
2005-05-31 |
2006-12-07 |
Sidney Kimmel Cancer Center |
Methods for immunotherapy of cancer
|
|
EP1909834A2
(en)
|
2005-07-18 |
2008-04-16 |
Critical Therapeutics, Inc. |
Use of hmgb1 antagonists for the treatment of inflammatory skin conditions
|
|
JP2009511452A
(ja)
|
2005-10-07 |
2009-03-19 |
プロイェクト、デ、ビオメディシナ、シーマ、ソシエダッド、リミターダ |
Ｃ型肝炎の予防および治療のための免疫刺激物質の組合せ
|
|
AU2006311752A1
(en)
|
2005-11-07 |
2007-05-18 |
Sidney Kimmel Cancer Center |
CD40 ligand fusion protein vaccine
|
|
WO2007054658A1
(en)
|
2005-11-14 |
2007-05-18 |
King's College London |
Control of immune responses
|
|
WO2007130725A2
(en)
*
|
2006-02-06 |
2007-11-15 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Use of hmgb1 for protection against ischemia reperfusion injury
|
|
WO2007103048A2
(en)
|
2006-03-01 |
2007-09-13 |
Regents Of The University Of Colorado |
Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity
|
|
US8802419B2
(en)
|
2006-03-02 |
2014-08-12 |
University Of Massachusetts |
Modified pathogens for use as vaccines
|
|
JP5683811B2
(ja)
*
|
2006-07-27 |
2015-03-11 |
タケダ ヴァクシーンズ， インコーポレイテッド |
キメラインフルエンザウイルス様粒子
|
|
US8564612B2
(en)
*
|
2006-08-04 |
2013-10-22 |
Apple Inc. |
Deep pixel pipeline
|
|
JP2010500034A
(ja)
*
|
2006-08-09 |
2010-01-07 |
メッドイミューン バクシーンズ，インコーポレイティド |
インフルエンザ赤血球凝集素変異体およびノイラミニダーゼ変異体
|
|
EP2857038B1
(en)
*
|
2006-09-18 |
2019-04-10 |
The Board of Trustees of the University of Arkansas |
Compositions and methods of enhancing immune responses
|
|
WO2008109825A2
(en)
|
2007-03-08 |
2008-09-12 |
Mayo Foundation For Medical Education And Research |
Inducing immune-mediated tumor cell death
|
|
CA2688548A1
(en)
*
|
2007-05-02 |
2009-01-15 |
Emory University |
Enhancement of glycoprotein incorporation into virus-like particles
|
|
US9125854B2
(en)
|
2007-10-30 |
2015-09-08 |
The Board Of Trustees Of The University Of Arkansas |
Compositions and methods of enhancing immune responses to flagellated bacterium
|
|
PT2214701T
(pt)
|
2007-11-01 |
2016-11-02 |
Univ Guelph |
Composições e métodos de potenciar respostas imunes a eimeria
|
|
NO2525817T3
(enExample)
|
2010-01-21 |
2018-01-06 |
|
|
|
BR112012031211A2
(pt)
|
2010-06-09 |
2018-01-30 |
Univ Arkansas |
métodos e vacina para reduzir a infecção causada pelo campylobacter
|
|
US20140328815A1
(en)
|
2011-11-11 |
2014-11-06 |
Nutrition Physiology Company, Llc |
Lactic Acid Bacteria And Their Use As Dietary Supplementals For Poultry
|